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Abstract
Introduction: Stakeholder engagement is an essential component of HIV clinical trials. We define stakeholder engagement as
an input by individuals or groups with an interest in HIV clinical trials to inform the design or conduct of said trials. Despite
its value, stakeholder engagement to inform HIV clinical trials has not been rigorously examined. The purpose of our system-
atic review is to examine stakeholder engagement for HIV clinical trials and compare it to the recommendations of the
UNAIDS/AVAC Good Participatory Practice (GPP) guidelines.
Methods: We used the PRISMA checklist and identified English language studies describing stakeholder engagement to
inform HIV clinical trials. Four databases (PubMed, Ovid, CINAHL and Web of Science) and six journals were searched, with
additional studies identified using handsearching and expert input. Two independent reviewers examined citations, abstracts
and full texts. Data were extracted on country, engagement methods, stakeholder types and purpose of stakeholder engage-
ment. Based on the GPP guidelines, we examined how frequently stakeholder engagement was conducted to inform clinical
trial research question development, protocol development, recruitment, enrolment, follow-up, results and dissemination.
Results and discussion: Of the 917 citations identified, 108 studies were included in the analysis. Forty-eight studies (44.4%)
described stakeholder engagement in high-income countries, thirty (27.8%) in middle-income countries and nine (8.3%) in low-
income countries. Fourteen methods for stakeholder engagement were identified, including individual (e.g. interviews) and
group (e.g. community advisory boards) strategies. Thirty-five types of stakeholders were engaged, with approximately half of
the studies (60; 55.6%) engaging HIV-affected community stakeholders (e.g. people living with HIV, at-risk or related popula-
tions of interest). We observed greater frequency of stakeholder engagement to inform protocol development (49 studies;
45.4%) and trial recruitment (47 studies; 43.5%). Fewer studies described stakeholder engagement to inform post-trial pro-
cesses related to trial results (3; 2.8%) and dissemination (11; 10.2%).
Conclusions: Our findings identify important directions for future stakeholder engagement research and suggestions for pol-
icy. Most notably, we found that stakeholder engagement was more frequently conducted to inform early stages of HIV clinical
trials compared to later stages. In order to meet recommendations established in the GPP guidelines, greater stakeholder
engagement across all clinical trial stages is needed.
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1 | INTRODUCTION
Engaging stakeholders in the clinical trial research process has
been well established as a method to improve research imple-
mentation, procedures, and outcomes [1,2]. Stakeholders can be
defined broadly as any individual or group who can have an
impact on or is affected by a clinical trial [3]. Some examples of
stakeholders include trial participants, members of local com-
munities in which a trial is conducted, governmental organiza-
tions and funders who shape the research process. Strong
stakeholder engagement can potentially result in trials that
more effectively address stakeholders’ needs and perspectives
[4], as well as improve health equity, access and participant
welfare [5]. Stakeholder engagement is particularly important in
HIV clinical trials, which require careful consideration of the
unique physical, psychological and social vulnerabilities associ-
ated with HIV infection [6] and subsequent ethical obligations
towards trial participants [7]. In addition, despite the dispropor-
tionate impact of the HIV epidemic on minority communities,
these populations are underrepresented in HIV research [8].
These factors make stakeholder engagement critical for building
effective and sustainable collaborations.
The field of HIV research has championed innovative stake-
holder engagement efforts, spurred partly by the activism of
those living with HIV. Following the efforts of the ACT-UP
movement, the National Institutes of Health (NIH) established
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community advisory boards (CABs) in the 1980s to help
design and implement research within the NIH trials network,
making CABs one of the earliest mandated forms of stake-
holder engagement in HIV trials in the United States [9]. The
first CABs in low- and middle-income countries were estab-
lished in the late 1990s [10]. Since these early efforts, further
advancements in stakeholder engagement have included the
development of guidance documents such as Principles of Com-
munity Engagement by the Centers for Disease Control and
Prevention [11], as well as guidelines specific to the conduct
of HIV research, including: Respect, Protect, Fulfill, a guidance
document for researchers involving men who have sex with
men (MSM) in the HIV research process [12]; the Stakeholder
Engagement Toolkit for HIV Prevention Trials [13]; Recommenda-
tions for Community Engagement in HIV/AIDS Research, devel-
oped by community stakeholders partnering with the NIH
[14]; and the Good Participatory Practice (GPP) guidelines for
stakeholder engagement in biomedical HIV prevention trials
[3]. Developed jointly by UNAIDS and the AIDS Vaccine Advo-
cacy Coalition (AVAC) in 2007, the GPP guidelines established
a framework for effective stakeholder engagement in HIV clin-
ical trials that are applicable to a broad range of stakeholders
and use of an array of engagement methods [3]. These guideli-
nes were revised in 2011 based on extensive consultation and
feedback with global stakeholders. The GPP guidelines
recommend stakeholder engagement as a continual process
throughout the stages of a clinical trial: research question
development, protocol development, recruitment, enrolment,
follow-up, trial results and dissemination.
Although the importance of stakeholder engagement for HIV
clinical trials is widely recognized, little is known about how
engagement strategies are being implemented in this field.
Existing literature is limited to examining the historical develop-
ment of stakeholder engagement [15], exploring single sites of
stakeholder engagement [16] and reviewing implementation
challenges [17]. The purpose of our systematic review is to
examine stakeholder engagement for HIV clinical trials and
compare it to GPP benchmarks. More data on how stakeholder
engagement is being conducted in-practice could help inform
GPP guidelines and local engagement strategies for specific
HIV trials. Five primary research questions are used to guide
our inquiry: (1) What are the geographical locations in which
stakeholder engagement is conducted for HIV clinical trials? (2)
What methods of stakeholder engagement have been used to
inform HIV clinical trials? (3) What types of stakeholders have
been engaged? (4) For what purpose has stakeholder engage-
ment been undertaken in relation to informing HIV clinical tri-
als? (5) What is the quality of reporting on stakeholder
engagement for HIV clinical trials? By examining how stake-
holder engagement for HIV clinical trials has been conducted
and reported, our review aims to provide a better understand-
ing of patterns and gaps in existing engagement efforts, point-
ing to opportunities for improvement in accordance with the
recommendations established by the GPP guidelines.
2 | METHODS
2.1 | Search strategy
We used the PRISMA checklist for reporting systematic
review findings (Figure 1). We searched English language
studies published before 9 August 2017. Search terms
included variations to capture the concept of stakeholder
engagement (community engage* OR community consult* OR
participatory OR community advis* OR stakeholder*) in com-
bination with the terms HIV and clinical trial*. We searched
four databases: PubMed, OVID, CINAHL, and Web of Science.
To supplement database results, we additionally searched six
HIV journals using their respective journal search functions:
Lancet HIV, Journal of the International AIDS Society, AIDS, Jour-
nal of Acquired Immune Deficiency Syndromes, AIDS Research
and Human Retroviruses and International Journal of STD &
AIDS. Finally, studies’ reference lists were handsearched for
additional articles to include. We also contacted three individ-
uals with relevant expertise to recommend additional refer-
ences for inclusion. These individuals were experts in the field
of stakeholder engagement for HIV clinical trials and/or princi-
pal investigators on NIH-funded projects examining the con-
duct of HIV research.
2.2 | Study selection
To be selected for review, a study had to describe some form
of stakeholder engagement undertaken for informing the design
or conduct of an HIV clinical trial. Two reviewers independently
screened all titles and abstracts returned from searches. Dis-
agreements were resolved through discussion with a third
reviewer. The full texts of selected abstracts were then read in
full independently by two reviewers for final inclusion and again
compared for agreement, with discrepancies resolved by third
reviewer. Duplicates were removed and reasons for excluding
abstracts and full texts were recorded at each selection stage.
A two-reviewer selection process was similarly applied to stud-
ies identified via reference list searching and expert input.
As the purpose of our review was to provide an overview
of stakeholder engagement for HIV clinical trials, we used a
broad definition of stakeholder engagement. Adapting descrip-
tions of stakeholders and advisory mechanisms for HIV pre-
vention trials outlined in the GPP guidelines [3], we defined
stakeholder engagement as any input sought from an individ-
ual or group with a stake in HIV clinical trials to inform the
design or conduct of said trials. Our definition of clinical trials
follows the NIH definition, which encompasses interventions
in both biomedical and behavioural outcomes [18]. Using this
definition allowed us to include studies describing stakeholder
engagement to inform both biomedical HIV-related trials (e.g.
vaccine and microbicide trials) and behavioural trials (e.g. trials
of behavioural interventions for HIV prevention). Regardless
of whether the trial was biomedical or behavioural, it had to
be related explicitly to HIV in order to be included in the
review; for example, we did not include behavioural trials for
prevention of sexually transmitted infections in general.
Recognizing that stakeholder engagement takes place along
a continuum from minimal to substantial involvement [2], we
did not limit selection of studies based on the extent of stake-
holder engagement in the studies identified. We also did not
limit inclusion of studies solely to stakeholder engagement
efforts undertaken for a current HIV clinical trial; studies
describing stakeholder engagement to inform future and/or
hypothetical HIV clinical trials (i.e. the field of HIV clinical trial
research in general) were also included. Studies were excluded
on the basis of not involving stakeholder engagement to
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inform HIV clinical trials as per our set definitions. We
excluded editorials and reviews.
2.3 | Data extraction and analysis
A data extraction chart was developed to record four character-
istics of studies included in the review: the geographical location
of engagement activities, the methods used for stakeholder
engagement, the types of stakeholders engaged and the purpose
of stakeholder engagement. Geographical location was extracted
based on the country where stakeholder engagement was
conducted using World Bank classifications (high-, middle- or
low-income countries) [19]. We did not extract data on the loca-
tion of the clinical trial given our focus on stakeholder engage-
ment. The purpose of stakeholder engagement refers to the
reason that it was undertaken relative to informing the conduct
of an HIV clinical trial. Our choice to extract descriptions of
purpose rather than outcome was again due to our selection
strategy: since we included studies of stakeholder engagement
to inform future/hypothetical HIV clinical trials, it was not always
possible to extract data on the impact or outcomes of stake-
holder engagement. However, all studies described (in varying
levels of detail) the purpose for which stakeholder engagement
was undertaken relative to inform HIV clinical trials.
Following data extraction, a series of analytic codes were
developed to categorize the purpose of stakeholder engage-
ment in each study by the stage of the HIV clinical trial research
process that stakeholder engagement was undertaken to
inform. Broad coding categories were initially developed based
on the seven stages of an HIV clinical trial process as outlined
in the GPP guidelines: research question development, protocol
development, trial recruitment, participant enrolment, follow-
up, results and dissemination [3]. We then used an open coding
process to develop and apply thematic codes to each study
based on the various reasons for which stakeholder engage-
ment was undertaken to inform any given stage in the HIV clini-
cal trial research process. Coding was conducted exhaustively
to categorize the potentially multiple reasons for conducting
stakeholder engagement in any one study. For example, if a
study included stakeholder engagement to both enhance the
ethical conduct of the trial as well as develop effective recruit-
ment strategies, the study would receive both codes.
Data analysis involved comparing our extracted and coded
data to three benchmarks outlined in the GPP guidelines [3].
First, given that GPP guidelines recommend use of an array
of stakeholder advisory mechanisms beyond the clinical trial
CABs, we identified and categorized all stakeholder engage-
ment methods used and calculated the number of studies
using each method. We did not assess the extent of stake-
holder engagement in each study because there are no stan-
dardized metrics [20]. Second, GPP guidelines stress the
identification of relevant trial stakeholders, noting a distinction
between community stakeholders (i.e. stakeholders represent-
ing the interests of persons participating in the trial and/or
affected by the trial) and other stakeholders with interests in
HIV clinical trials more broadly (i.e. funders, government rep-
resentatives). As such, our analysis aimed to identify and cate-
gorize the types of stakeholders presently engaged in HIV
clinical trials, again calculating the number of studies engaging
each stakeholder type. Finally, given that GPP guidelines rec-
ommend stakeholder engagement throughout the entire clini-
cal trial, we categorized purpose of engagement according to
the seven stages of the HIV clinical trial process.
2.4 | Quality of reporting on stakeholder
engagement
To assess reporting quality, we adapted the short form of a
checklist on Guidance for Reporting Involvement of Patients
452 citations identified: database search results 
92 from PubMED 
128 from Ovid 
51 from CINAHL 
181 from Web of Science 
450 citations identified: target journal search results
29 from Lancet HIV
175 from J Int AIDS Soc
12 from AIDS
52 from J Acquir Immune Defic Syndr
60 from AIDS Res Hum Retroviruses
122 from Int J STD AIDS
Titles/abstracts screened for eligibility by 
two reviewers 
(n = 902) 
Titles/abstracts excluded: 
284 database results 
361 target journal results 
(n = 645) 
Full-texts assessed for 
eligibility by two 
reviewers 
(n = 272)
Full-text articles excluded: 
93 database results (62 did not meet 
inclusion criteria, 31 duplicates) 
71 target journal results (64 did not 
meet inclusion criteria, 7 duplicates) 
(n = 164)
Studies included in review 
(n = 108) 
15 citations identified 
using other strategies 
(handsearching reference 
lists and consultation with 
experts) 
Figure 1. Search and selection strategy results for a systematic review of stakeholder engagement for HIV clinical trials.
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and the Public (GRIPP) in health research [21] into a reporting
quality assessment tool. All studies were assessed by one
reviewer per study for inclusion of the following information:
(1) description of stakeholder engagement purpose; (2) explana-
tion for choice of stakeholder engagement method; (3) descrip-
tion of the development of stakeholder engagement methods
used; (4) the number of stakeholders engaged; (5) the results of
stakeholder engagement; (6) the impact of stakeholder engage-
ment on trial design/conduct; and (7) discussion of limitations
to the stakeholder engagement method used. In each study,
these seven reporting details were assessed as being either
present or absent. Analysis of reporting quality was conducted
for all 108 studies overall, as well as by the type of trial that
engagement was conducted to inform (i.e. behavioural preven-
tion trials, biomedical prevention trials, treatment trials or com-
bination/trial type not specified). Additionally, in accordance
with the Sex and Gender Equity in Research (SAGER) guidelines
[22], we assessed two indicators of the extent to which studies
reported on stakeholders’ sex and/or gender (depending on
which variable was relevant to the study): the number of stake-
holders engaged by sex and/or gender category, and reporting
of stakeholder results disaggregated by sex and/or gender.
3 | RESULTS
As illustrated in Figure 1, a total of 452 titles and abstracts
were returned for screening from our four database searches.
Of these, 168 full texts were assessed, resulting in 75 studies
included for review from the database search strategy. Our tar-
get journal search produced 402 titles and abstracts for
screening, of which 89 full texts were assessed and 18 studies
were retained for review. Our additional search strategies
(handsearching of reference lists and inquiry with field experts)
yielded an additional 15 studies for inclusion. In total, 108
studies were selected for final inclusion and data extraction.
The oldest study included in our review was published in 1988
[23], and the most recent was published July 2017 [24]. Of the
108 studies in our review, 11 studies conducted stakeholder
engagement to inform behavioural HIV prevention trials, 70
for biomedical HIV prevention trials and 10 for HIV treatment
trials. In the remaining 17 studies, stakeholder engagement
was conducted to inform either a combination of HIV-related
trial types or an unspecified type of HIV clinical trial (i.e. HIV
clinical trials in general, without specifying whether prevention
or treatment, behavioural or biomedical) (see Appendix 1).
Analysis of the data extracted from these 108 studies was
guided by our five research questions on the characteristics
and reporting of stakeholder engagement to inform HIV clini-
cal trials. The following subsections present in detail the
results of each of these five analyses. In terms of the geo-
graphical location of stakeholder engagement, the majority of
studies in our review described engagement conducted in
high-income countries. Engagement methods used included
both individual and group methods. We identified a wide array
of stakeholders engaged, ranging from stakeholders directly
involved in clinical trial processes to stakeholders on the
periphery of HIV clinical trials. Engagement was found to be
undertaken much more often for informing earlier stages of
HIV clinical trials as compared to later stages. Finally, we
found that reporting on the results of stakeholder
engagement and limitations associated with engagement are
the main gaps in the quality of reporting.
3.1 | Location of stakeholder engagement
Of the 108 studies, 48 studies (44.4%) conducted stakeholder
engagement in high-income countries [5,23,25-70]. In contrast,
fewer studies conducted stakeholder engagement in middle-
(30 studies; 27.8%) [71-100] and low-income (nine studies;
8.3%) [101-109] countries. The location of stakeholder engage-
ment could not be discerned in six studies (5.6%) [110-115], and
fifteen studies (13.9%) [16,24,116-128] conducted stakeholder
engagement in multiple countries at different income levels.
3.2 | Methods of stakeholder engagement for HIV
clinical trials
In addition to CABs, we identified 13 other methods of con-
ducting stakeholder engagement across the studies in our
review, for a total of 14 distinct methods (Table 1). Methods
were separated into five individual methods (i.e. methods
involving input or feedback by one stakeholder at a time, such
as interviews) and nine group methods (i.e. methods involving
input or feedback in a collective format, such as focus groups).
As shown in Table 1, individual methods appeared in 75
(69.4%) studies and group methods were used in 66 studies
(61.1%). The most frequently used method for stakeholder
engagement was stakeholder interviews, followed by focus group
discussions. CABs were used as often as surveys/questionnaires.
Five methods were used by only one study each: concept map-
ping [35], cognitive mapping [77], crowdsourcing [72] (having a
group participate in solving a problem and then sharing the solu-
tion with the public), participatory mapping [102] and dramatic
performances [112]. All five of these studies were published from
the year 2005 onward, suggesting more recent diversification of
stakeholder engagement methods. Additionally, many studies
used a combination of both individual and group methods
for stakeholder engagement; for example, 19 studies (17.6%)
paired focus group discussions with stakeholder interviews
[5,16,27,32,33,79,82,89,90,96,98,100,101,106,108,109,116,
125,128].
3.3 | Types of stakeholders engaged for HIV clinical
trial research
Table 2 presents our analysis of the types of stakeholders
engaged throughout all studies reviewed. We identified 35
unique types of stakeholders, which can be grouped into eight
subcategories under three broader categories: trial-related
stakeholders, community stakeholders and broader stakeholders.
Similar to the categories of stakeholders identified in the GPP
guidelines as being relevant to HIV clinical trial research [3], we
found that the types of stakeholders engaged ranged from indi-
viduals or groups in close proximity to the trial (e.g. trial partici-
pants themselves) to broader stakeholders who hold an interest
in HIV trial outcomes more generally (e.g. policymakers).
As shown in Table 2, 29 studies included participant trial-
related stakeholders in their engagement efforts and 36 stud-
ies engaged non-participant trial-related stakeholders, the lat-
ter of which included community advisory board/group
members, trial staff, and trial funders. Collectively these
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Table 1. Methods of stakeholder engagement (n = 108)
Methods of
stakeholder engagement Method description Studies using each method
Number of studies
using each methoda (%)
Individual
engagement
methods
Stakeholder
interviews
Interviews conducted with individuals
identified as key stakeholders
[5,16,26-28,32,33,44,49,54,
56,58,62,68,69,72,76,79,82,
86,88-91,93,95-98,100-102,
106,108-111,113,116,117,
124,125,128]
43 (39.8%) 75 (69.4%)
Surveys/
questionnaires
Surveys or questionnaires about
stakeholder perspectives
administered by mail, online or in-
person
[24,26,30,31,43,48,49,52,53,56-58,
62-67,80,81,83,87,114,123]
24 (22.2%)
Individual
stakeholder
consultations
Consultations on trial issues/
processes sought with specific key
informants
[30,34,40,45,50,72,
103-105,118-121]
13 (12.0%)
Cognitive
mapping
Mixed-methods approach involving
stakeholder interviews, map
sketching and observational
techniques
[77] 1 (0.9%)
Concept
mapping
Mixed-methods approach involving
initial stakeholder idea generation
and subsequent stakeholder-led
categorization and ranking of
submitted ideas.
[35] 1 (0.9%)
Group engagement
methods
Focus group
discussions
Multiple stakeholders led in a group
discussion by a facilitator
[5,16,27,32,33,37-39,45-47,
50,55,60,71,74,79,82,85,89,
90,94,96,98,100,101,106-109,
116,125,128]
33 (30.6%) 66 (61.1%)
Community
advisory
boards/groups
A formally established group of
stakeholders representing
community interests and providing
a link between trial researchers
and the broader community
[23,25,26,28-30,34,36,37,
42,50,51,75,80,84,92,102,
112,115,118-122]
24 (22.2%)
Community
forums or
meetings
Public or invitational meetings held to
inform the community about trial
issues/processes and obtain
feedback from community members
[30,34,61,70,75,92,99,103,108,
112,118,121,122,126,127]
15 (13.9%)
Stakeholder
workshops/
education
sessions
Events where stakeholders are
convened to solve specific trial-
related problem(s) and/or build
capacity to understand trial issues/
processes
[26,30,41,75,78,102,108,
115,118,126]
10 (9.3%)
Community
working
groups
Group of stakeholders convened to
solve or advise on trial-related
problems
[59,75,120] 3 (2.8%)
Media outreach
campaigns
Informing the broader community
about trial issues/processes
through mass media and inviting
commentary/feedback from
stakeholders reached through
media messaging
[34,73,92] 3 (2.8%)
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stakeholders are in closest proximity to the HIV clinical trial
research process.
The community stakeholders category presented in Table 2
comprises stakeholders drawn from communities (socially or
geographically defined) in which HIV clinical trials may be
embedded. Approximately half of all studies included HIV-
affected community stakeholders in their engagement efforts,
a subcategory of community stakeholders which encompassed
key populations of interest, people involved in HIV advocacy,
people living with HIV, and partners and family members of
people living with HIV. The most frequently engaged type of
stakeholder was populations of interest (40 studies; 37.0%),
defined on the basis of socio-demographic characteristics,
occupation, relationship status, HIV risk status or other fac-
tors that made a population of particular interest to an HIV
clinical trial. In contrast to this targeted approach in defining
stakeholders, members of the general public were engaged in
just 12 studies (11.1%). Thirteen studies (12%) described
engagement conducted with community stakeholders or com-
munity representatives without specifying further as to what
aspect of the community these stakeholders represent
[29,30,56,59,70,92,98,108,112,120,122,125,128].
Stakeholder types encompassed by the broader stakehold-
ers category in Table 2 differ substantially from lay commu-
nity members. Studies engaging broader stakeholders sought
input from medical, academic and governmental experts,
including three types of healthcare stakeholders (23 studies),
eight types of research stakeholders (13 studies) and three
types of governmental stakeholders (12 studies). It is impor-
tant to note that while these are not the most frequently
engaged stakeholders in HIV clinical trials, limiting investiga-
tion of engagement to ‘community’ members/representatives
would fail to capture the involvement of these groups.
3.4 | Purpose of stakeholder engagement for HIV
clinical trials
Table 3 presents the results of our coding for the purpose of
stakeholder engagement in the studies reviewed, organized by
the seven stages of HIV clinical trial research.
We identified 25 distinct purposes for which stakeholder
engagement was undertaken. The most frequently reported
purpose for stakeholder engagement was for understanding
factors affecting trial recruitment (29 studies). This includes
studies that examined how stakeholders’ attitudes about HIV
trial participation may impact recruitment; for example, examin-
ing how stakeholders’ perceptions of early trial termination
might affect willingness to participate in future vaccine trials
[33,62]. Additional examples of studies using stakeholder
engagement for this purpose include studies investigating barri-
ers and facilitators to trial participation among specific popula-
tions [55,87]. The second and third most frequent purpose for
conducting stakeholder engagement was to inform the ethical
conduct of the trial (16 studies) and to develop trial tools (15
studies) respectively. In informing the ethical conduct of trials,
stakeholders were engaged for providing input on ethics-
related concerns, either in terms of the overall trial process
[70,76,88,99] or in relation to particular aspects of the trial; for
example, trial stopping rules [78], trial communication strategies
[123] and concepts of fairness in the research relationship [94].
By examining the purpose of stakeholder engagement by
research stage in Table 3, we observed that stakeholder
engagement was conducted more often to inform the earlier
stages of trials. More studies described undertaking stake-
holder engagement to inform the trial protocol development
stage (49 studies; 45.4%) than any other research stage.
Nearly the same volume of studies (47; 43.5%) undertook
stakeholder engagement to inform trial recruitment. Stake-
holder engagement to inform the final two stages of the
research process was described least frequently, with just
three studies engaging stakeholders to inform the trial results
stage and eleven to inform dissemination of trial results. This
disparity in studies conducting stakeholder engagement for
purposes across the seven stages of research is more clearly
visualized by Figure 2.
3.5 | Quality of stakeholder engagement reporting
Table 4 summarizes the results of our assessment of report-
ing quality, indicating the number of studies meeting seven
Table 1. (Continued)
Methods of
stakeholder engagement Method description Studies using each method
Number of studies
using each methoda (%)
Crowdsourcing Having a group participate in solving
a problem and then sharing the
solution with the public
[72] 1 (0.9%)
Participatory
mapping
Community members collaborate with
field workers to develop a map
depicting local knowledge and
community needs
[102] 1 (0.9%)
Dramatic
performances
Skits or plays performed to inform
about trial-related issues/processes
and prompt feedback from the
audience
[112] 1 (0.9%)
aFor totals and percentages of overall individual versus group methods, studies that used multiple types of individual or group methods were only
counted once for each of the two method categories.
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Table 2. Types of Stakeholders Engaged (n = 108)
Types of stakeholders engaged Studies engaging each stakeholder type
Number of
studies engaging
each stakeholder
typea (%)
Trial-related
stakeholders
Participant
trial-related
stakeholders
Trial participants (past or current) [16,30,31,36,49,56,62,70,74,79-81,
83,86,87,91,98,101,103,106,108,
112,113,116,118,125,128]
27 (25.0%) 29 (26.9%)
Partners of trial participants [75,79,106] 3 (2.8%)
Potential trial participants (not further
specified)
[81,94] 2 (1.9%)
Non-
participant
trial-related
stakeholders
Community advisory board/group
members (not further specified)
[28,30,35,37,71,74,77-79,84,
85,88,89,92,98,101,108,
115,116,118-120,124,127]
24 (22.2%) 36 (33.3%)
Trial research team members (e.g. site
staff, recruitment officers)
[16,30,56,58,71,74,76,78,88,89,98,
101–103,108,112–114,116,124,127,128]
22 (20.4%)
Trial sponsors [61,78,83,88] 4 (3.7%)
Community
stakeholders
HIV-affected
community
stakeholders
Populations of interest (e.g. based on
race, sexual orientation, occupation,
geographical location, risk status)
[16,28,33,37-39,41-45,47,48,
50,52,54,55,63-69,72,77,85,
90,93,95-97,100,102,109,
117,121,123,125,128]
40 (37.0%) 60 (55.6%)
People involved in HIV advocacy (e.g.
community outreach)
[16,23,25,28,30,33,34,36,
51,57,61,78,96,100,105,118,127]
17 (15.7%)
People living with HIV (not further
specified)
[5,26,27,32,36,53,57,60,109] 9 (8.3%)
Partners of people living with HIV [101] 1 (0.9%)
Family members/guardians of people
living with HIV
[23,104] 2 (1.9%)
Local
community
stakeholders
Community leaders (e.g. political,
traditional, religious)
[5,16,23,29,32,36,45,60,75,82,93,96,98,
100,102,105,106,109,112,121,122]
21 (19.4%) 41 (38.0%)
Community stakeholders/
representatives (not further
specified)
[29,30,56,59,70,92,98,108,
112,120,122,125,128]
13 (12.0%)
General community members (general
public)
[26,30,46,48,72,73,82,92,99,107,115,121] 12 (11.1%)
Local media representatives [29,79,88] 3 (2.8%)
School teachers/principals [75,85] 2 (1.9%)
Food/recreation facility owners/
managers
[102] 1 (0.9%)
Organizational
community
stakeholders
Non-governmental organizations [16,29,75,76,88,92,102,106,
110,111,121,122]
12 (11.1%) 20 (18.5%)
Community-based organizations/groups
serving people living with HIV
[5,16,26,32,36,79,82,111,118] 9 (8.3%)
Community-based organizations (not
further specified)
[29,36,75,79,85,102,121,122] 8 (7.4%)
Human rights groups [111] 1 (0.9%)
Broader
stakeholders
Healthcare
stakeholders
Healthcare providers [27,29,33,34,36,42,57,60,
75,82,93,96,100,106,109,
118,121,126,128]
19 (17.6%) 23 (21.3%)
Healthcare facility managers/staff [23,75,85,93,94,126] 6 (5.6%)
Drug industry representatives [61] 1 (0.9%)
Research
stakeholders
IRB/Ethics Committee Membersb [27,30,70,83,88] 5 (4.6%) 13 (12.0%)
HIV researchers [24,61,76,118] 4 (3.7%)
Clinical researchers [70,94] 2 (1.9%)
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criteria adapted from the GRIPP2 checklist to improve report-
ing of stakeholder involvement in health research [21]. We
also disaggregated our analysis of stakeholder engagement
reporting quality by the type of HIV-related trial that the
stakeholder engagement was meant to inform (see
Appendix 1).
While all 108 studies included in the review described at
least one purpose for conducting stakeholder engagement,
Table 4 demonstrates that most studies also provided details
on the development of the engagement methods, the number
of stakeholders engaged and the results of stakeholder engage-
ment. ‘Results of stakeholder engagement’ refers to reporting
the information obtained through a study’s engagement
method, such as reporting findings from focus group discus-
sions [27,71,101]. This differs from reporting the outcome of
stakeholder engagement, which we defined as reporting on the
impact that stakeholder engagement made on the design or
conduct of an HIV clinical trial, such as describing how the
results of crowdsourcing were subsequently used to develop a
clinical trial’s intervention [72]. We found that stakeholder
engagement outcomes were assessable among 41 studies (67
studies included in the review conducted stakeholder engage-
ment to inform future/hypothetical trials); however, among
these 41 studies, only 29 (70%) met the reporting criteria,
meaning 30% of studies with the opportunity to report on
stakeholder engagement outcomes did not do so. Additionally,
of all 108 studies reviewed, 60 (55.6%) reported the number of
engaged stakeholders by sex and/or gender category; however,
only four studies reported stakeholder engagement results dis-
aggregated by sex and/or gender category [38,52,74,87].
4 | DISCUSSION
This systematic review described stakeholder engagement for
HIV clinical trials and compared this engagement to GPP rec-
ommendations. Our review suggests critical gaps in
stakeholder engagement that should be examined and
addressed in the field of HIV clinical trial research.
First, we found more of the studies included in our review
conducted stakeholder engagement in HICs compared to
LMICs. This finding is consistent with a review of clinical trial
priority setting processes [129]. One potential explanation for
these results may be that there is a greater proportion of HIV
clinical trials conducted in HIC settings, as a review of infec-
tious disease trials registered with ClinicalTrials.gov found that
the greatest proportion of all registered HIV trials were
located in North America and Europe [130]. In addition, con-
ducting stakeholder engagement in LMICs may be hindered
by limited resources, communication barriers, and mistrust of
research [16]. However, while stakeholder engagement may
be challenging to conduct in LMICs, these are also the con-
texts in which stakeholder engagement may be most impor-
tant [131]. Our results demonstrate a need for more evidence
to inform HIV clinical trials in LMICs.
Second, our data suggest that while many methods are used,
most stakeholder engagement is conducted using researcher-
driven, top-down methods. This often involves formal social
science methods such as in-depth interviews or focus group
discussions. It is unclear how effective these methods are for
fostering meaningful partnerships and continuous dialogue as
the GPP guidelines recommend [3]. Additionally, the extent to
which top-down engagement methods can inform the design
and conduct of HIV clinical trials depends entirely on trial
researchers. Thus, while the GPP guidelines recommend that
trial researchers carefully consider and select from the range of
possible advisory mechanisms [3], the reliance on top-down,
expert-driven stakeholder engagement suggests the need for
these and other guidance documents to consider innovative,
bottom-up engagement strategies. For example, crowdsourcing
approaches that allow community members a more participa-
tory role in informing HIV clinical trials could supplement exist-
ing stakeholder engagement strategies [132]. Engagement
methods that follow a participatory model can help to achieve
Table 2. (Continued)
Types of stakeholders engaged Studies engaging each stakeholder type
Number of
studies engaging
each stakeholder
typea (%)
Ethics experts (not further specified) [70,120] 2 (1.9%)
Survey design experts [72] 1 (0.9%)
Research advocates [70] 1 (0.9%)
Women’s health researchers [34] 1 (0.9%)
Anthropologists [72] 1 (0.9%)
Governmental
stakeholders
Government health research
organizations
[30,35,40,61,127] 5 (4.6%) 12 (11.1%)
Government health officials [40,61,70,102,118] 5 (4.6%)
Policymakers and government
representatives (not further
specified)
[29,76,88,122] 4 (3.7%)
aFor totals and percentages of subcategories of stakeholders, studies that engaged multiple types of stakeholders within the same subcategory
were only counted once per subcategory.
bEngagement of IRB/Ethics Committee Members refers to engagement efforts outside of the standard IRB/Ethics review process.
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Table 3. Purpose of stakeholder engagement (n = 108)
Purpose of stakeholder engagement,
by research stage
Studies using stakeholder
engagement for each purpose
Number of studies using
each purposea (%)
Research
question
development
Understanding stakeholder perspectives on trial
feasibility/acceptability
[5,27,30,32,82,106,112,121,122] 9 (8.3%) 15 (13.9%)
Setting research priorities/goals [36,40,61,84,117,118] 6 (5.6%)
Protocol
design
Informing ethical conduct of trial (e.g. participant
rights, stopping rules, communication, IRB
submission, confidentiality, concepts of fairness)
[23,36,67,68,70,76,78,88,94,99,
115,117,120,123,125,127,128]
17 (15.7%) 49 (45.4%)
Developing trial tools (e.g. interventions,
measurements, training materials, participant
education materials)
[24,25,29,35-39,42,72,74,
103,106,107,119]
15 (13.9%)
Developing stakeholder engagement strategies
for trial
[16,50,57,59,70,75,76,102,
110,111,113,116,122,124]
14 (13.0%)
Developing trial protocol (in general or not
further specified)
[29,34,36,51,109] 5 (4.6%)
Selecting trial sites [34,37,105] 3 (2.8%)
Determining trial participation incentives/
compensation
[25,94] 2 (1.9%)
Securing healthcare services for trial participants [126] 1 (0.9%)
Developing trial site management strategies [114] 1 (0.9%)
Recruitment Understanding factors affecting trial recruitment
(e.g. attitudes about trial participation)
[31,33,43,45,46,48,52-55,58,60,
62-66,69,85,87,89,90,95,
97,98,100,106,109,110]
29 (26.9%) 47 (43.5%)
Building community education/awareness to
enhance recruitment and/or community
support for trial
[26,29,30,41,73,75,92,112,
115,121,122]
11 (10.2%)
Developing trial recruitment strategies [29,34,47,50,68,77,93] 7 (6.5%)
Building credibility for trial among community to
enhance recruitment
[37] 1 (0.9%)
Enrolment Enhancing the informed consent process [49,53,56,71,80,81,96,99,101,108,
112,120,128]
13 (12.0%) 13 (12.0%)
Follow-up Developing retention strategies [34,36,50,77,93,104] 6 (5.6%) 17 (15.7%)
Understanding factors affecting trial adherence/
retention
[28,31,44,79,91] 5 (4.6%)
Addressing participants’ concerns as they arise in
trial
[75,108,118,122] 4 (3.7%)
Understanding participants’ expectations about
the trial
[86] 1 (0.9%)
Building community education/awareness to
enhance retention
[115] 1 (0.9%)
Results Developing post-trial processes (e.g. post-trial
access to medication)
[62,83] 2 (1.9%) 3 (2.8%)
Reviewing/interpreting trial results [29] 1 (0.9%)
Dissemination Communicating results to broader stakeholders [23,25,36,110,117,118,122] 7 (6.5%) 11 (10.2%)
Communicating results to trial participants [62,75,86,110,118,122] 6 (5.6%)
Developing academic products based on trial
results
[29] 1 (0.9%)
aFor totals and percentages by research stage, studies that conducted stakeholder engagement for multiple purposes within the same research
stage were only counted once per research stage.
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more meaningful inclusion of stakeholders and greater opportu-
nities to change the status quo [2].
Third, we found that stakeholder engagement was predomi-
nately conducted to inform early trial stages. These findings are
comparable to those of studies examining stakeholder engage-
ment in other fields of health research [133,134]. Both of these
studies emphasize the importance of engaging stakeholders
throughout all stages of the research, a recommendation also
posed by the GPP guidelines for HIV clinical trials [3]. In order
to meet these benchmarks for GPP, our results suggest that
greater efforts are particularly needed to engage stakeholders
in the later stages of HIV clinical trial research. Future research
should examine innovative methods to foster opportunities for
stakeholder contributions at these points in the research pro-
cess. Additionally, while multiple guidance documents exist to
promote meaningful and effective stakeholder engagement
[3,11-14], HIV clinical trial teams should consider how to tailor
these recommendations so that engagement efforts account for
the specificities of the type of trial being conducted as well as
for local contexts (e.g. social, political). These efforts by HIV
researchers could help to establish models for stakeholder
engagement in clinical trial research more broadly.
Our findings should be considered alongside broader fac-
tors that inform the engagement process and researcher-sta-
keholder relationship in HIV clinical research. The extent to
which stakeholders are engaged is shaped not only by the
clinical trial team, but also by the structural contexts within
which clinical trial research is embedded. As noted by others
[15], it is important to consider how funders and corporate
interests influence stakeholder engagement. For example, the
funding of many HIV trials by high-income countries may inad-
vertently assert norms and activities (e.g. community advisory
boards) that are not locally driven. The impact of global
resource disparities on stakeholder engagement should also
be considered, particularly for the potential to reproduce
inequalities in terms of which stakeholders are engaged [16].
Thus, while the results of our review help to make visible
some of the gaps in current stakeholder engagement for HIV
clinical trials, more research is needed to account for why
these gaps occur and how best to address these gaps as a
product of broader structural contexts.
There are several important limitations to this review. First,
we did not assess quality of engagement. However, there is a
notable lack of quality measurement tools for stakeholder
engagement [20], as well as disagreement regarding whether
and how to determine what level of engagement is appropri-
ate [135]. Second, our review does not examine the outcomes
of stakeholder engagement; however, only 41 studies (38%) in
our review provided information on engagement outcomes.
Future reviews should focus on systematically assessing
1
1
. Research 
Queson
5 studies 
(13.9%)
2. Protocol
49 studies 
(45.4%)
3.
Recruit
47 stu
(43.5
4 ment
dies 
%)
. Enrolment
13 studies 
(12.0%)
5. Follow-up
17 studies 
(15.7%)
6. Re
3 st
(2.
Dsults
udies 
8%)
7. 
isseminaon
11 studies 
(10.2%)
Figure 2. Summary of the purpose of stakeholder engagement by clinical trial research stage.
Table 4. Quality of stakeholder engagement reporting (n = 108 studies)
Reporting quality criteria
Studies meeting reporting
quality criteria
Number of
studies (%)
Aim Describes the purpose of stakeholder
engagement
[5,16,23-128] 108 (100%)
Methods Explains reasons for choice of stakeholder
engagement method(s)
[23,27,29,35,36,38,39,41,63,69,72,73,77,78,81,86,88,92,99,101,
102,104-106,115,116,120-122,124]
30 (27.8%)
Describes development of engagement method
(s) used
[5,16,23,26,27,29,30,32-36,38-41,43-49,
52-60,62-64,66,69,70,72,73,75,77-83,85-90,
92-106,108-111,114,116,119,120,122,124-126,128]
82 (75.9%)
Reports the number of all stakeholders engaged [16,24-33,35,36,38-40,43-49,52-57,59,60,62-69,71,
74-83,85-103,106,108-111,113,114,116,123-125,127,128]
82 (75.9%)
Results Describes results of stakeholder engagement [5,16,23,24,26-36,38-41,43-46,48,49,52-83,85-102,104-106,
108-111,113,114,116-128]
97 (89.8%)
Outcomesa Discusses impact of stakeholder engagement on
HIV clinical trial (where applicable)
[23,25,29-31,34,36,39,41,47,49,50,61,72,73,75,78,92,103-105,
108,109,115,118-122]
29 (70%)a
Reflections Discusses limitations of stakeholder engagement [5,16,24,26-29,31-36,41,43-46,48,52-56,58,60,62-64,68,71,
73-76,78-83,87,88,90,91,93-96,98-102,110,111,114,
116,120,123,125,127]
62 (57.4%)
aReporting on outcomes was assessed only among 41 studies that were not related to future/hypothetical trials.
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engagement outcomes in relation to methods used and stake-
holders engaged. Third, our finding that fewer studies con-
ducted stakeholder engagement in LMICs may be attributable
in part to our search strategy being limited to English lan-
guage studies only. Manuscript selection bias (i.e. the overrep-
resentation of scientific publications from HICs) may also play
a role [136]. Fourth, the extent to which this review can pro-
vide an overview of stakeholder engagement for HIV clinical
trials is necessarily dependent on the extent to which these
activities are reported. It is possible that more engagement
takes place “behind the scenes” of clinical trial research with-
out making its way into published accounts of trial results.
Improved reporting standards in accordance with guidance
documents such as those used in our analysis of reporting
quality [21] may help to provide further evidence for all
research teams seeking to enhance their own engagement
approaches, regardless of HIV trial type.
5 | CONCLUSIONS
The results of this systematic review of stakeholder engage-
ment for HIV clinical trials have implications for research
and policy. First, our finding of fewer studies conducting
stakeholder engagement in LMICs suggests the need for fur-
ther reporting on stakeholder engagement in these settings
[131]. Additional resources and regulations to support and
sustain stakeholder engagement in these settings may be
necessary to address potential barriers to engagement. Sec-
ond, despite engagement recommendations outlined in com-
prehensive guidelines [3] and funding allocated on the part
of national and international funding bodies to support
engagement activities [20], our findings suggest that stake-
holder engagement is not being conducted evenly to inform
all stages of the HIV clinical trial process. More research is
needed in order to understand barriers and facilitators to
involving stakeholders in the later stages of HIV clinical trial
research specifically, as well as which methods of engage-
ment would be most conducive to involving stakeholders in
trial results and dissemination processes. Funders should
additionally consider adding specifications to stakeholder
engagement requirements to help address this gap, such as
requiring clinical trial researchers to include detailed engage-
ment plans for each stage of the trial process. Future
research could then examine whether and how stakeholder
engagement changes over time in response to such efforts.
Finally, to address gaps identified in reporting quality, HIV
research journals should consider implementing policies
about reporting stakeholder engagement. Checklists for
reporting on stakeholder engagement [21,133] may help to
promote greater transparency as to what engagement efforts
are undertaken in trials and how this engagement shapes
the research process. This information will be particularly
valuable for undertaking future research to evaluate the
quality of stakeholder engagement.
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